CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04648826
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:22.266234+00:00
- Published At
- 2021-12-17T00:00:00+00:00
- Record Updated At
- 2021-12-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Sarcomas", "Melanomas", "Germ Cell Tumors", "Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas)", "Pulmonary Metastases"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-12-17"- protocolSection.identificationModule.nctId
"NCT04648826"- protocolSection.identificationModule.officialTitle
"Phase I/II Evaluation of Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.